KRBP vs. CYAD, AIM, PMCB, APTO, SNTI, TVGN, IKT, COEP, ONVO, and GENE
Should you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Celyad Oncology (CYAD), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Aptose Biosciences (APTO), Senti Biosciences (SNTI), Tevogen Bio (TVGN), Inhibikase Therapeutics (IKT), Coeptis Therapeutics (COEP), Organovo (ONVO), and Genetic Technologies (GENE). These companies are all part of the "medical" sector.
Kiromic BioPharma (NASDAQ:KRBP) and Celyad Oncology (NASDAQ:CYAD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.
Celyad Oncology has higher revenue and earnings than Kiromic BioPharma.
In the previous week, Kiromic BioPharma had 2 more articles in the media than Celyad Oncology. MarketBeat recorded 2 mentions for Kiromic BioPharma and 0 mentions for Celyad Oncology. Kiromic BioPharma's average media sentiment score of 0.00 equaled Celyad Oncology'saverage media sentiment score.
Celyad Oncology received 284 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 67.70% of users gave Celyad Oncology an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote.
10.9% of Kiromic BioPharma shares are held by institutional investors. 20.6% of Kiromic BioPharma shares are held by company insiders. Comparatively, 0.9% of Celyad Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Celyad Oncology beats Kiromic BioPharma on 5 of the 8 factors compared between the two stocks.
Get Kiromic BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiromic BioPharma Competitors List
Related Companies and Tools
